BACKGROUND: Alternatives to the available stavudine-containing paediatric fixed-dose combination (FDC) tablets are rapidly needed due to concerns regarding the cumulative toxicity of long-term stavudine exposure. We report the bioavailability and short-term safety of a novel paediatric FDC tablet of zidovudine (ZDV)/lamivudine (3TC)/nevirapine (NVP; 30/15/28 mg) in HIV-infected children. METHODS: In this Phase I/II open-label pharmacokinetic study, 42 children weighing 6-30 kg treated with NVP-based HAART for ≥4 weeks were randomized to receive the FDC tablets (GPO-VIR Z30) or the liquid formulations. Dosing was weight-based. Intensive 12-h blood sampling was performed after 2 weeks; subjects then crossed-over to the alternate formulation at equal doses and sampling repeated 2 weeks later. Pharmacokinetic parameters were determined by non-compartmental analysis. Buccal-swab samples were collected for cytochrome P450 (CYP)2B6 polymorphism analysis. RESULTS: With the FDC tablet, the geometric mean (90% CI) area under the curve (AUC) for ZDV, 3TC and NVP was 1.58 (1.49-1.68), 7.78 (7.38-8.19) and 68.88 (62.13-76.36) μg•h/ml, respectively. Rules for NVP therapeutic inadequacy were defined a priori, and despite lower NVP exposure with the tablet (P<0.001), the levels remained therapeutically adequate. ZDV AUC was similar between formulations. 3TC exposure was significantly higher with the tablet but comparable to historical data in adults and children taking branded tablets. While receiving the tablet, NVP AUC in children with CYP2B 516 GG (45%), GT (45%) and TT (10%) genotypes were 67.0, 74.5 and 106.4 μg•h/ml, respectively (P=0.04). CONCLUSIONS: Disparities in drug exposure between formulations were observed; however, the FDC tablet delivered therapeutically adequate exposures of each drug and could well play an important role in simplifying antiretroviral treatment for children.
RCT Entities:
BACKGROUND: Alternatives to the available stavudine-containing paediatric fixed-dose combination (FDC) tablets are rapidly needed due to concerns regarding the cumulative toxicity of long-term stavudine exposure. We report the bioavailability and short-term safety of a novel paediatric FDC tablet of zidovudine (ZDV)/lamivudine (3TC)/nevirapine (NVP; 30/15/28 mg) in HIV-infectedchildren. METHODS: In this Phase I/II open-label pharmacokinetic study, 42 children weighing 6-30 kg treated with NVP-based HAART for ≥4 weeks were randomized to receive the FDC tablets (GPO-VIR Z30) or the liquid formulations. Dosing was weight-based. Intensive 12-h blood sampling was performed after 2 weeks; subjects then crossed-over to the alternate formulation at equal doses and sampling repeated 2 weeks later. Pharmacokinetic parameters were determined by non-compartmental analysis. Buccal-swab samples were collected for cytochrome P450 (CYP)2B6 polymorphism analysis. RESULTS: With the FDC tablet, the geometric mean (90% CI) area under the curve (AUC) for ZDV, 3TC and NVP was 1.58 (1.49-1.68), 7.78 (7.38-8.19) and 68.88 (62.13-76.36) μg•h/ml, respectively. Rules for NVP therapeutic inadequacy were defined a priori, and despite lower NVP exposure with the tablet (P<0.001), the levels remained therapeutically adequate. ZDV AUC was similar between formulations. 3TC exposure was significantly higher with the tablet but comparable to historical data in adults and children taking branded tablets. While receiving the tablet, NVP AUC in children with CYP2B 516 GG (45%), GT (45%) and TT (10%) genotypes were 67.0, 74.5 and 106.4 μg•h/ml, respectively (P=0.04). CONCLUSIONS: Disparities in drug exposure between formulations were observed; however, the FDC tablet delivered therapeutically adequate exposures of each drug and could well play an important role in simplifying antiretroviral treatment for children.
Authors: Jacques Fellay; Catia Marzolini; Emma R Meaden; David J Back; Thierry Buclin; Jean Philippe Chave; Laurent A Decosterd; Hansjakob Furrer; Milos Opravil; Giuseppe Pantaleo; Dorota Retelska; Lidia Ruiz; Alfred H Schinkel; Pietro Vernazza; Chin B Eap; Amalio Telenti Journal: Lancet Date: 2002-01-05 Impact factor: 79.321
Authors: A I Veldkamp; G J Weverling; J M Lange; J S Montaner; P Reiss; D A Cooper; S Vella; D Hall; J H Beijnen; R M Hoetelmans Journal: AIDS Date: 2001-06-15 Impact factor: 4.177
Authors: K H Moore; J E Barrett; S Shaw; G E Pakes; R Churchus; A Kapoor; J Lloyd; M G Barry; D Back Journal: AIDS Date: 1999-11-12 Impact factor: 4.177
Authors: R Bruno; M B Regazzi; V Ciappina; P Villani; P Sacchi; M Montagna; R Panebianco; G Filice Journal: Clin Pharmacokinet Date: 2001 Impact factor: 6.447
Authors: K Luzuriaga; Y Bryson; G McSherry; J Robinson; B Stechenberg; G Scott; M Lamson; S Cort; J L Sullivan Journal: J Infect Dis Date: 1996-10 Impact factor: 5.226
Authors: Mina Nikanjam; Desiré Kabamba; Tim R Cressey; David Burger; Francesca T Aweeka; Edward P Acosta; Stephen A Spector; Edmund V Capparelli Journal: Antimicrob Agents Chemother Date: 2012-08-06 Impact factor: 5.191
Authors: Esther J H Janssen; Diane E T Bastiaans; Pyry A J Välitalo; Annemarie M C van Rossum; Evelyne Jacqz-Aigrain; Hermione Lyall; Catherijne A J Knibbe; David M Burger Journal: Br J Clin Pharmacol Date: 2017-02-14 Impact factor: 4.335
Authors: Mina Nikanjam; Desiré Kabamba; Tim R Cressey; David Burger; Francesca T Aweeka; Edward P Acosta; Stephen A Spector; Edmund V Capparelli Journal: Antimicrob Agents Chemother Date: 2012-08-06 Impact factor: 5.191
Authors: Victor Musiime; Philip Kasirye; Bethany Naidoo-James; Patricia Nahirya-Ntege; Tawanda Mhute; Adrian Cook; Lincoln Mugarura; Marshall Munjoma; Navdeep K Thoofer; Emmanuel Ndashimye; Immaculate Nankya; Moira J Spyer; Margaret J Thomason; Wendy Snowden; Diana M Gibb; Ann Sarah Walker Journal: AIDS Date: 2016-07-17 Impact factor: 4.177
Authors: Kathleen Doherty; Shaffiq Essajee; Martina Penazzato; Charles Holmes; Stephen Resch; Andrea Ciaranello Journal: BMC Health Serv Res Date: 2014-05-02 Impact factor: 2.655